Retatrutide Achieves 28.3% Weight Loss in Landmark Phase 3 TRIUMPH-1 Trial
Eli Lilly's investigational triple agonist retatrutide has delivered its most compelling clinical evidence yet, with the pivotal TRIUMPH-1 Phase 3 trial confirming average weight loss of up to 28.3% at 80 weeks — and 30.3% in a longer extension — setting a new benchmark for obesity pharmacotherapy.
What the TRIUMPH-1 Trial Found
Announced on 21 May 2026, the TRIUMPH-1 trial enrolled 2,339 adults with obesity or overweight and at least one weight-related comorbidity. Participants were randomised to receive retatrutide at doses of 4 mg, 9 mg, or 12 mg, or placebo, over 80 weeks.
The results were striking across all active doses:
| Dose | Average Weight Loss | Average Kilograms Lost |
|---|---|---|
| 4 mg | 19.0% | 21.4 kg |
| 9 mg | 25.9% | 29.2 kg |
| 12 mg | 28.3% | 31.9 kg |
| Placebo | 2.2% | 2.5 kg |
Notably, 65.3% of participants on the 12 mg dose achieved a BMI below 30 — falling below the clinical threshold for obesity — by week 80. In a pre-specified 104-week extension for participants with a baseline BMI of 35 or above, those continuing on 12 mg achieved an average weight loss of 30.3%, equivalent to 38.6 kg (85 lbs).
Beyond the Scales: Cardiometabolic Benefits
Weight loss alone does not tell the full story. TRIUMPH-1 also demonstrated significant improvements across a range of cardiometabolic risk factors compared to placebo, including:
- Waist circumference — a key marker of visceral fat and metabolic risk
- Non-HDL cholesterol — associated with cardiovascular disease risk
- Triglycerides — elevated levels are linked to heart disease and fatty liver
- Systolic blood pressure — reductions lower the risk of stroke and heart attack
- High-sensitivity C-reactive protein (hsCRP) — a marker of systemic inflammation
These secondary endpoints reinforce retatrutide's potential as a broad metabolic therapy, not merely a weight-loss agent. The drug's unique triple-agonist mechanism — simultaneously activating GIP, GLP-1, and glucagon receptors — is thought to drive these additional benefits, particularly through glucagon receptor activity, which directly stimulates hepatic fat oxidation.
Safety Profile: Consistent With the Incretin Class
The adverse event profile in TRIUMPH-1 was broadly consistent with other GLP-1-based therapies. The most commonly reported side effects were nausea, diarrhoea, constipation, and vomiting — predominantly mild to moderate and occurring during dose escalation. Discontinuation rates due to adverse events were 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg), compared with 4.9% in the placebo group.
A notable finding across the TRIUMPH programme has been dysesthesia — an abnormal skin sensation — reported in a subset of participants at higher doses. Most cases resolved during treatment, and the overall safety profile was considered acceptable by investigators.
Where the TRIUMPH Programme Stands Now
TRIUMPH-1 is one of several trials within Eli Lilly's comprehensive Phase 3 programme. Other key studies include:
- TRIUMPH-4 (completed December 2025): Evaluated retatrutide in adults with obesity and knee osteoarthritis, showing 28.7% weight loss at 68 weeks and meaningful reductions in knee pain.
- TRIUMPH-2: Ongoing — evaluating retatrutide in adults with obesity and type 2 diabetes.
- TRIUMPH-3: Ongoing — a cardiovascular and renal outcomes trial in patients with established cardiovascular disease.
- TRANSCEND-T2D-1 (June 2026): Demonstrated 16.8% weight loss and a 2.0% reduction in HbA1c in patients with type 2 diabetes.
Eli Lilly is expected to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in the fourth quarter of 2026, with a potential approval decision anticipated in late 2027 or early 2028.
What This Means for Australians
Retatrutide is not currently approved by the Therapeutic Goods Administration (TGA) and is not available by prescription in Australia. The drug is not listed on the Australian Register of Therapeutic Goods (ARTG), and importing unapproved therapeutic goods is illegal under Australian law.
For Australians living with obesity or related metabolic conditions, the TRIUMPH-1 results are nonetheless significant. They confirm that retatrutide represents a meaningful step forward in pharmacological options for weight management — potentially surpassing the efficacy of currently available TGA-approved agents such as semaglutide (Wegovy) and tirzepatide (Mounjaro).
The most realistic pathway to access in Australia remains participation in registered clinical trials. Interested individuals should speak with their GP or an obesity medicine specialist, who can advise on eligibility for trials listed on the Australian New Zealand Clinical Trials Registry (ANZCTR) or clinicaltrials.gov.
Commercial availability in Australia is estimated no earlier than 2027–2028, accounting for FDA approval, a subsequent TGA review process (typically 6–18 months after international approval), and potential Pharmaceutical Benefits Scheme (PBS) listing, which can add a further 12–24 months.
Retatrutide is an investigational drug not approved by the TGA. This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
